SATIVEX for ALS (Lou Gehrig’s Disease)

“The results suggest that THC:CBD may serve as a valuable addition in the spectrum of symptomatic therapy in ALS.”

A new study published in BMC Neurology provides the first real world data (outside a clinical trial) on the dosing of THC:CBD in amyotrophic lateral sclerosis (ALS).

ALS is a severe, progressive and incurable neurodegenerative disorder.

The study found thatTHC:CBD (Sativex) may serve as a valuable addition in the spectrum of symptomatic therapy in ALS.”

Patients reported high satisfaction with the treatment.

Sativex (GW Pharmaceuticals) increasingly being used off-label for spasticity treatment of persons with ALS.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s